In the subgroup of patients with NEC, Rbinap was independently associated with a significantly lower risk of death (HR 0.54, 95% CI (0.31–0.95), p = 0.033) on multivariate analyses adjusted for primary tumor location, NEC subtype, Ki-67 and extra-hepatic metastases (Table 4). Here, MKI67 is linked to neoplasm.